Q1 2025 ANI Pharmaceuticals Inc Earnings Call Transcript

May 9, 2025 / 12:00 PM GMT

Release Date Price: €65.5 (+5.65%)

Transcript 8-K10-Q8-K

Key Points

Positve

ANI Pharmaceuticals Inc (ANIP) reported record revenue and adjusted EPS for the first quarter of 2025, driven by strong performance in their generics business and increased demand for cortrophin gel.
The company raised its 2025 revenue guidance to $768 million to $793 million, reflecting a growth of 25% to 29% over 2024.
Cortrophin gel revenues increased by 43% over the first quarter of 2024, with a record number of new patient starts and new cases initiated.
The generics business delivered exceptionally strong first-quarter revenues of $98.7 million, an increase of 41% over the prior year period.
ANI Pharmaceuticals Inc (ANIP) has a strong balance sheet, with 90% of total company revenues coming from finished goods manufactured in the US, and less than 5% direct reliance on China.

Negative

The performance of retina products in the US was impacted by market access challenges for Medicare patients and turnover in the sales force.
Non-gap gross margin decreased by approximately 130 basis points from the prior year period, driven by mix and significant growth of royalty-bearing products.
The company experienced turnover in its US ophthalmology sales force, impacting the performance of retina products.
There were challenges in market access for Medicare patients due to insufficient funding for patient support foundations, affecting products reimbursed under Medicare Part B.
The company anticipates that second-quarter revenues will be lower than the first quarter due to the phasing of generics revenue and the end of exclusivity for certain products.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ANIP.OQ - ANI Pharmaceuticals Inc
Q1 2025 ANI Pharmaceuticals Inc Earnings Call
May 09, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Please stand by. Your program is about to begin. If you need assistance during your conference today, please press 0.

Good day everyone, and welcome to today's ANI Pharmaceuticals Inc. First quarter 2025 earnings results call.

Please note this call is being recorded.

After the speaker's opening remarks, there will be a question and answer session.

If you would like to ask a question during this time, simply press the star, then the number one on your telephone keypad.

If you would like to withdraw your question, please press the star key, then number 2 on your telephone keypad.

It is now my pleasure to turn the conference over to Lisa Wilson.

-------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.